Expertise in
1
conditions

Amichay Meirovitz-Rotstein

Dental Branch, 
Jerusalem, JM, IL 
Expertise in
1
conditions
Dental Branch, 
Jerusalem, JM, IL 

Overview

Amichay Meirovitz-Rotstein practices practicing medicine in Jerusalem, Israel.

Meirovitz-Rotstein is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Neuroendocrine Tumor, Head and Neck Squamous Cell Carcinoma (HNSCC), Merkel Cell Carcinoma, Breast Cancer, and Awake Craniotomy.

They are actively involved in clinical research, co-authoring 84 peer reviewed articles and participating in 1 clinical trial.

Locations

Dental Branch, Jerusalem, JM, Israel
Other Locations
14 Kaplan Street, Petah Tiqwa, M 49202, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3

84 Total Publications

Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinib.
Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinib.
Journal: Frontiers in molecular biosciences
Published: May 11, 2026

Frequently Asked Questions about Amichay Meirovitz-Rotstein

Is Amichay Meirovitz-Rotstein a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Amichay Meirovitz-Rotstein is classified as an Advanced expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Amichay Meirovitz-Rotstein participate in research or clinical trials?

Yes. Amichay Meirovitz-Rotstein has published 84 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Amichay Meirovitz-Rotstein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Meirovitz-Rotstein's expertise for a condition
ConditionClose
      View All 23 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile